Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

FRANKLIN J CHARNEY

Allopathic & Osteopathic Physicians Surgery

NPI
1366441404
CMS profile
288861
Location
DENTON, TX

General Payments · PY2018–2024

$516,797.03

  • Reported across 175 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$91,233.43

31 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $91,000.00 28
Travel and Lodging $233.43 3

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Takeda Pharmaceuticals U.S.A., Inc. $91,233.43 31

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $36,651.04 12
PY2019 $56,259.14 19
PY2020 $82,700.00 25
PY2021 $83,300.00 24
PY2022 $104,655.17 41
PY2023 $61,998.25 23
PY2024 $91,233.43 31

Payment records · PY2024 (31)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
Takeda Pharmaceuticals U.S.A., Inc. $3,600.00 01/17/2024 Consulting Fee Undisputed 01/23/2026 1137508061 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,600.00 01/17/2024 Consulting Fee Undisputed 01/23/2026 1137508065 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,600.00 02/14/2024 Consulting Fee Undisputed 01/23/2026 1137508068 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,600.00 02/14/2024 Consulting Fee Undisputed 01/23/2026 1137508072 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,600.00 03/11/2024 Consulting Fee Undisputed 01/23/2026 1137508076 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,600.00 03/11/2024 Consulting Fee Undisputed 01/23/2026 1137508079 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,600.00 04/17/2024 Consulting Fee Undisputed 01/23/2026 1137508083 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,600.00 04/17/2024 Consulting Fee Undisputed 01/23/2026 1137508087 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,600.00 05/10/2024 Consulting Fee Undisputed 01/23/2026 1137508091 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,600.00 05/10/2024 Consulting Fee Undisputed 01/23/2026 1137508095 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,600.00 06/10/2024 Consulting Fee Undisputed 01/23/2026 1137508098 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,600.00 06/10/2024 Consulting Fee Undisputed 01/23/2026 1137508102 CMS
Takeda Pharmaceuticals U.S.A., Inc. $900.00 07/12/2024 Consulting Fee Undisputed 01/23/2026 1137508106 CMS
Takeda Pharmaceuticals U.S.A., Inc. $65.53 07/12/2024 Travel and Lodging Undisputed 01/23/2026 1137508110 CMS
Takeda Pharmaceuticals U.S.A., Inc. $900.00 07/12/2024 Consulting Fee Undisputed 01/23/2026 1137508113 CMS
Takeda Pharmaceuticals U.S.A., Inc. $64.32 07/12/2024 Travel and Lodging Undisputed 01/23/2026 1137508117 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,600.00 07/12/2024 Consulting Fee Undisputed 01/23/2026 1137508121 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,600.00 07/12/2024 Consulting Fee Undisputed 01/23/2026 1137508124 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,600.00 08/09/2024 Consulting Fee Undisputed 01/23/2026 1137508128 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,600.00 08/09/2024 Consulting Fee Undisputed 01/23/2026 1137508132 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,600.00 09/11/2024 Consulting Fee Undisputed 01/23/2026 1137508136 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,600.00 09/11/2024 Consulting Fee Undisputed 01/23/2026 1137508139 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,600.00 10/09/2024 Consulting Fee Undisputed 01/23/2026 1137508143 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,600.00 10/09/2024 Consulting Fee Undisputed 01/23/2026 1137508147 CMS
Takeda Pharmaceuticals U.S.A., Inc. $900.00 10/16/2024 Consulting Fee Undisputed 01/23/2026 1137508151 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,800.00 11/06/2024 Consulting Fee Undisputed 01/23/2026 1137508155 CMS
Takeda Pharmaceuticals U.S.A., Inc. $103.58 11/06/2024 Travel and Lodging Undisputed 01/23/2026 1137508158 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,600.00 11/13/2024 Consulting Fee Undisputed 01/23/2026 1137508162 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,600.00 11/13/2024 Consulting Fee Undisputed 01/23/2026 1137508166 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,700.00 12/09/2024 Consulting Fee Undisputed 01/23/2026 1137508170 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,600.00 12/09/2024 Consulting Fee Undisputed 01/23/2026 1137508173 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.